Replimune Group, Inc. (REPL)
- Sector
- Biotechnology
- Last price
- $12.11
- As of
Kresmion compiles this page from REPL's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Replimune Group, Inc. (REPL): 6 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-16.
See the full REPL dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for REPL on one page. Preview it with sample data, then open it live with a free account.
Preview the REPL dossierActive signals for REPL
- highCONSENSUS_BUY
7 tracked funds increased REPL this 2026Q2, institutional consensus
- highCONSENSUS_BUY
3 tracked funds increased REPL this 2026Q2, institutional consensus
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +359% to REPL (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +672% to REPL (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +567% to REPL (2026Q2)
FREE, NO ACCOUNT
Every signal on REPL, as it fires
You are seeing 5 of 17 signals recorded on REPL since 2026-05-26.
The five above landed across 2 days. The other 12 were recorded on 2 other days. 10 of the 17 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in REPL (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| D. E. Shaw & Co., Inc.CUSIP 76029N106 · 2026Q2 | $19.8M | 0.01% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 76029N106 · 2026Q2 | $9.1M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 76029N106 · 2026Q2 | $8.7M | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 76029N106 · 2026Q2 | $8M | 0.01% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 76029N106 · 2026Q2 | $1.8M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 76029N106 · 2026Q2 | $441K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, REPL
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
REPL mentioned in Kresmion daily briefs
REPL against its peers
REPL's return on equity of -188.9% ranks in the 12th percentile of 11 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-03-31.
| Metric | REPL | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 81.4M | n/a | 5 |
| Operating margin | n/a | -81.7% | n/a | 6 |
| Net margin | n/a | -106.9% | n/a | 6 |
| Return on equity | -188.9% | -40.6% | 13 | 11 |
| 1 year | 165.6% | 26.9% | 96 | 11 |
Peers (15): VOR, BCAX, LBRX, NBTX, JANX, ORIC, IMTX, MNKD, DMRA, MGTX, DRTS, INBX, SVRA, TYRA, ANAB. Left out: TRAX (no annual filing), AVLN (no annual filing), LTGO (no annual filing), AKTS (no annual filing), KARD (no annual filing), AAPG (period gap), SPTX (no annual filing), ANL (period gap), COAG (no annual filing), KALV (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (REPL: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow REPL on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to REPL for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.